Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches
April 24, 2018 at 12:49 PM EDT
Before Tuesday, 90 percent of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) analysts were buying the stock. But one analyst has diluted ...